Circassia Pharmaceuticals (GB:NIOX) has released an update.
Circassia Pharmaceuticals reports a robust financial performance for H1 2024, with revenue up 12% to £21.0 million and adjusted EBITDA increasing to £7.1 million, demonstrating strong sales and operational efficiency. The company also highlights a solid balance sheet with £21.5 million in cash and announces a tender offer to return £21.0 million to shareholders. These developments reflect the company’s continued growth in the medical devices market for asthma diagnosis and management.
For further insights into GB:NIOX stock, check out TipRanks’ Stock Analysis page.
